Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Assembly Biosciences, Inc. (ASMB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1300-0.1500 (-6.58%)
At close: 04:00PM EST
2.1200 -0.01 (-0.47%)
After hours: 04:28PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Intermediate-term KST

Intermediate-term KST

Previous Close2.2800
Open2.2900
Bid2.1200 x 3000
Ask2.1600 x 1000
Day's Range2.1000 - 2.2900
52 Week Range2.1000 - 7.0200
Volume943,134
Avg. Volume790,112
Market Cap101.945M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.58
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ASMB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Assembly Biosciences, Inc.
    ENTA: Lowering target price to $91.00ENANTA PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $91.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • GlobeNewswire

    Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio

    Newly selected preclinical core inhibitor candidate, ABI-4334, demonstrates single-digit nanomolar potency against both pgRNA encapsidation and cccDNA formation ABI-H3733 shows favorable pharmacokinetics and safety in Phase 1a study; Phase 1b study expected to begin in 2022 Vebicorvir Phase 2 open-label study data demonstrate the contribution of core inhibition to deepen viral suppression; Oral presentation scheduled for November 14 at 10 am ET SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE N

  • GlobeNewswire

    Assembly Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the third quarter ended September 30, 2021. John McHutchison, AO, MD, chief executive officer and president of Assembly Bio, said, “We are excited to advance our latest core inhibitor ABI-4334, with a potential best-in-class p

  • GlobeNewswire

    Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

    HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breakingSOUTH SAN FRANCISCO, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that clinical and preclinical data from its HBV core inhibitor program will be featured in one oral and two poster presentations, including one late breakin

Advertisement
Advertisement